Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease have?
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease has 1,654 citations in the OpenAlex counts ScholarIQ stores.
When was Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease published?
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease has 2014 year in the ScholarIQ index.
What is the open-access status of Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease has bronze oa status in the ScholarIQ index.
What is the DOI of Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?
The DOI for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is on the source record.
What is the PMID of Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?
The PMID for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is on the source record.
What is the OpenAlex record for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?
The OpenAlex for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is on the source record.